$12.11
14.42%
Nasdaq, Nov 16, 11:29 am EST. Market open.
ISIN
US86627R1023
Symbol
SMMT

Summit Therapeutics PLC Sponsored ADR Stock price

$14.15
-1.37 8.83% 1M
-4.64 24.69% 6M
-3.34 19.10% YTD
-4.11 22.51% 1Y
+12.31 669.02% 3Y
+8.95 172.12% 5Y
+2.35 19.92% 10Y
+3.96 38.86% 20Y
Nasdaq, Closing price Fri, Nov 13 2026
-0.93 6.14%
ISIN
US86627R1023
Symbol
SMMT
Industry

Is Summit Therapeutics PLC Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,087 stocks worldwide.

Key metrics

Basic
Market capitalization
$11.3b
Enterprise Value
$10.6b
Net debt
positive
Cash
$690.7m
Shares outstanding
793.1m
Valuation
P/E
negative
P/S | estimate
- | 4,060.5
EV/Sales | estimate
- | 3,812.7
EV/FCF | ex SBC
negative | negative
P/B
18.0
Financial Health
Equity Ratio
87.7%
Return on Equity
-163.9%
ROCE
-134.9%
ROIC
-
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$384.0m | -
SBC as % of FCF
-
SBC Growth 1Y
-26.2%
Share Count Growth 1Y
6.8%
Shareholder Yield
-6.8%
Financials
Revenue | estimate
$0.0 | $2.8m
EBITDA
$-874.7m
EBIT
$-874.8m
Net Income
$-856.1m
Free Cash Flow | ex SBC
$-459.8m | $-843.9m
Growth
Revenue | estimate
- | -
EBITDA
-15.2%
EBIT
-15.2%
Net Income
-14.7%
Free Cash Flow
-121.7%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow | ex SBC
- | -
More
EPS
$-1.1
FCF per Share
$-0.6
Short interest
26.7%
Employees
265
Rev per Employee
$0.0

Summit Therapeutics PLC Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

24 Analysts have issued a Summit Therapeutics PLC Sponsored ADR forecast:

17x Buy
71%
7x Hold
29%

Analyst Opinions

24 Analysts have issued a Summit Therapeutics PLC Sponsored ADR forecast:

Buy
71%
Hold
29%

Summit Therapeutics PLC Sponsored ADR Events

Past Events
JUL
23
Q2 2026 Earnings Call
4 months ago
JUN
8
Goldman Sachs 47th Annual Global Healthcare Conference 2026
5 months ago
JUN
1
Special Call - Summit Therapeutics Inc.
6 months ago
MAR
11
The Citizens Life Sciences Conference 2026
8 months ago
MAR
2
TD Cowen 46th Annual Health Care Conference
9 months ago
FEB
23
Q4 2025 Earnings Call
9 months ago
JAN
12
44th Annual J.P. Morgan Healthcare Conference
10 months ago
DEC
3
Evercore 8th Annual Healthcare Conference
12 months ago
DEC
2
Citi Annual Global Healthcare Conference 2025
12 months ago
NOV
18
Jefferies London Healthcare Conference 2025
12 months ago
NOV
10
UBS Global Healthcare Conference 2025
about one year ago
OCT
20
Q3 2025 Earnings Call
about one year ago

Financial data from Summit Therapeutics PLC Sponsored ADR

Jun '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 306 306
25% 25%
-
- Research and Development Expense 569 569
63% 63%
-
-875 -875
15% 15%
-
- Depreciation and Amortization 0.17 0.17
70% 70%
-
EBIT (Operating Income) EBIT -875 -875
15% 15%
-
Net Profit -856 -856
15% 15%
-

In millions USD.

Don't miss a Thing! We will send you all news about Summit Therapeutics PLC Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Summit Therapeutics PLC Sponsored ADR Stock News

Negative
Barrons
●
about 3 hours ago
Summit Therapeutics stock sinks as regulators decline to approve ivonescimab, a next-generation cancer therapy backed by AstraZeneca.
Negative
Market Watch
●
about 4 hours ago
The regulator told Summit Therapeutics that the lung-cancer drug needs to prove it can help people live longer.
Negative
Investors Business Daily
●
about 21 hours ago
The FDA said Summit Therapeutics' lung cancer drug ivonescimab, developed in China, failed to show a statistically significant survival benefit.
More Summit Therapeutics PLC Sponsored ADR News

Company Profile

Summit Therapeutics Plc operates as a holding company, which engages in the discovery, development, and commercialization of antibiotic medicines. The company operates through the Drug Development segment, which covers its research and development activities carried out by the Group. Summit Therapeutics was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, the United Kingdom.

Head office United Kingdom
CEO Mr. Duggan
Employees 265
Founded 2003
Website www.smmttx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today